This CDC report provides updated data related to HIV prevalence among people who inject drugs, documenting findings that underscore the need for low-barrier access to comprehensive and integrated needs-based syringe service programs for necessary prevention and
Breadcrumb
- Home
- Resources and Tools
Resources and Tools
This document describes the critical role that peers have in developing and delivering care for people with HIV and OUD and how a state’s Medicaid program can serve as an essential fiscal resource in supporting peer services.
This tool aims to assist HIV primary care teams that work in a range of clinical settings to develop and provide enhanced integration of behavioral health (BH) services.
This discussion guide is intended to elicit a comprehensive and concrete conversation about language, stigma, and discrimination as a means of strengthening care systems and ensuring that people who seek care for HIV and/or substance use disorders, including opioid use disorder, are treated with
Transgender people and communities, including nonbinary people, have specific needs within harm reduction programs.
A recent study published in Drug and Alcohol Dependence found evidence for racial/ethnic disparities in buprenorphine distribution across the United States.
In recent years, the gap in the rate of opioid overdoses among Black and white Americans has narrowed significantly, with increases in Black mortality driven in part by the addition of synthetic opioids to other drugs.
This technical package, a collaborative effort between CDC and NASTAD, provides a broad framework as well as evidence-informed strategies and approaches to support the planning, design, implementation, and sustainability of new and existing syringe services programs (SSPs).
Opioid agonist treatment (OAT) is the provision of medications (methadone and buprenorphine) that activate the opioid receptors to prevent withdrawal and reduce cravings for opioids.
Pagination
- Previous page ‹‹
- Page 2
- Next page ››